BCR and acute lymphoblastic leukemia: Albeit preliminary, the data presented here indicate that cotreatment with nilotinib and ruxolitinib can more effectively eliminate imatinib-insensitive LPCs through a deeper suppression of BCR–ABL/JAK2 activity both in vitro and in humanized Ph+ALL mice.